Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi ® in 17 Middle Eastern and North African countries. Over 15,000 US health care providers have prescribed Winlevi® to date which represents 88% of total health care providers in dermatology. Hikma demonstrates strong performance in the dermatology market in the MENA region and is ranked among the top 10 companies in this therapeutic area. Their significant experience in commercialization in the MENA region gives us great confidence in their ability to successfully register and market Winlevi®. DisclaimerSome of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information.

Source: The North Africa Journal October 02, 2023 05:04 UTC